(Q31883223)

English

Interferon-beta1a administration results in a transient increase of serum amyloid A protein and C-reactive protein: comparison with other markers of inflammation

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Interferon-beta1a administration results in a transient increase of serum amyloid A protein and C-reactive protein: comparison with other markers of inflammation (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

0 references

author name string

Boylan MT

1

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Crockard AD

2

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Duddy ME

3

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Armstrong MA

4

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

McMillan SA

5

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Hawkins SA

6

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2001

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

immunology Letters

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

75

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

191-197

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Murine serum amyloid A3 is a high density apolipoprotein and is secreted by macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma clearance kinetics of the amyloid-related high density lipoprotein apoprotein, serum amyloid protein (apoSAA), in the mouse. Evidence for rapid apoSAA clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Apolipoprotein A-I and apolipoprotein SAA half-lives during acute inflammation and amyloidogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum amyloid A protein is elevated in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The neuroendocrine axis in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Production of serum amyloid A and C-reactive protein by HepG2 cells stimulated with combinations of cytokines or monocyte conditioned media: the effects of prednisolone

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Human serum amyloid A has cytokine-like properties

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in plasma cytokines induced by interferon-beta1a treatment in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Does interferon beta cause initial exacerbation of multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum interferon beta-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple sclerosis progression in a natural history study: predictive value of cerebrospinal fluid free kappa light chains

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Monocyte activation in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900310-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0165-2478(00)00310-2

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31883223&oldid=1965101743"